3
Total investments
1
Early stage
0
Mid stage
0
Late stage
6y
Years active
Portfolio
2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Angel Investor
Aug 2023
The BAG Collective is a collective of angel investors from top tech companies and startups that invests intellectual, social and financial capital in seed to Series A startups around the world. Our collective believes in and support founders who build ethical, high-growth technology companies.
Board Member, Dompé Canada
Oct 2021
Dompé farmaceutici is an international biopharmaceutical company involved in all activities of the pharmaceutical value chain, from research to development, production and marketing. As a long-established family company, we blend the stability that comes from our 130-year heritage with the agility and dynamism of a start-up.
We can turn transformative breakthroughs into treatments because we have the right qualities and capabilities to deliver new drugs. Our 160,000 square meter R&D and production site in L’Aquila, Italy, is the heart of Dompé. Here, we conduct vital research, and produce and distribute our primary care and biotech products.
Primary Care includes a broad spectrum of over-the-counter treatment solutions, prescription medications, supplements and medical devices. Our Biotech focuses on the development of treatments for rare diseases. The main therapeutic areas include pain relief, inflammation, ophthalmology, diabetes care, nutrition and oncology.
In the pursuit of improving human health, our R&D strives to break through in unconventional places. This is what led us to Nerve Growth Factor (NGF), a Nobel Prize-winning discovery made in 1986. We leveraged 50 years of research to transform this discovery into a breakthrough treatment. Our human recombinant NGF, cenegermin, is the first treatment for a rare degenerative eye disease, neurotrophic keratitis. That deep appreciation of science keeps us committed to investigating neurotrophins.
Our relentless pursuit in identifying new treatments for diseases allowed us to harness the potential of bioinformatics to accelerate the drug discovery process. The result is Exscalate, a structure-based virtual screening platform developed in-house and currently one of the most powerful supercomputing and artificial intelligence platforms for drug testing.
We are focused on the road ahead. Our hunger to deliver what patients need from science keeps us focused on what matters.
We embrace the challenge in science.
Experience · 7 entries
All (7)
Investments (3)
Board (2)
2023
Angel Investor
Aug 2023
The BAG Collective is a collective of angel investors from top tech companies and startups that invests intellectual, social and financial capital in seed to Series A startups around the world. Our collective believes in and support founders who build ethical, high-growth technology companies.
2021
Board Member, Dompé Canada
Oct 2021
Dompé farmaceutici is an international biopharmaceutical company involved in all activities of the pharmaceutical value chain, from research to development, production and marketing. As a long-established family company, we blend the stability that comes from our 130-year heritage with the agility and dynamism of a start-up.
We can turn transformative breakthroughs into treatments because we have the right qualities and capabilities to deliver new drugs. Our 160,000 square meter R&D and production site in L’Aquila, Italy, is the heart of Dompé. Here, we conduct vital research, and produce and distribute our primary care and biotech products.
Primary Care includes a broad spectrum of over-the-counter treatment solutions, prescription medications, supplements and medical devices. Our Biotech focuses on the development of treatments for rare diseases. The main therapeutic areas include pain relief, inflammation, ophthalmology, diabetes care, nutrition and oncology.
In the pursuit of improving human health, our R&D strives to break through in unconventional places. This is what led us to Nerve Growth Factor (NGF), a Nobel Prize-winning discovery made in 1986. We leveraged 50 years of research to transform this discovery into a breakthrough treatment. Our human recombinant NGF, cenegermin, is the first treatment for a rare degenerative eye disease, neurotrophic keratitis. That deep appreciation of science keeps us committed to investigating neurotrophins.
Our relentless pursuit in identifying new treatments for diseases allowed us to harness the potential of bioinformatics to accelerate the drug discovery process. The result is Exscalate, a structure-based virtual screening platform developed in-house and currently one of the most powerful supercomputing and artificial intelligence platforms for drug testing.
We are focused on the road ahead. Our hunger to deliver what patients need from science keeps us focused on what matters.
We embrace the challenge in science.
2020
Board Member
Feb 2020
For fifteen years, Aspire has been the Bay Area’s leader in effective supplemental education programming. By gathering a small community of educators stocked with content expertise and emotional intelligence, Aspire has been able to promise - and deliver - real results to thousands of Bay Area students. In our fifteen years, we’ve served over 15,400 students
Through our educational mentorship program, we empower our students with the skills to become independent, active learners. Then we invite them to be trained in social-emotional skills and then mentor a younger student in literacy through Community Reading Buddies.
2018
Associate Director, Commercial Strategy & Pharmaceutical Development
Mar 2018
As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.
Santen Pharmaceutical Official Social Media Global Terms of Use
https://www.santen.com/en/legal/
2016
Associate Brand Manager
Jan 2016
Plum, PBC is home to Plum Organics, a values-driven company committed to nourishing the next generation with great tasting, nutritious food from high chair to lunchbox.
Plum Organics is a group of extremely passionate people that truly love what they do and why they do it. They are parents, aunts, uncles, big brothers… tooth fairies. They are curious connoisseurs and joy seeking foodies that have come together to discover, celebrate & create all things healthy, inventive & yum
For more information about Plum Organics, visit www.plumorganics.com. You can also follow us on Facebook (https://www.facebook.com/PlumOrganics) and Twitter (@plumorganics).
For open positions at Plum Organics, check out:
http://hire.jobvite.com/CompanyJobs/Careers.aspx?k=JobListing&c=qHC9Vfw7&v=1
Plum, PBC is committed to providing equal opportunity for employees and applicants in all aspects of the employment relationship, without regard to race, color, sex, sexual orientation, gender identity, national origin, citizenship, marital status, veteran status, disability, age, religion or any other classification protected by law.
Show all 7 entries ↓
Investment activity
2020–2023 · 3 investments
Recent (last 2 years)Earlier
